tallglass13
Well-Known Member
- Messages
- 287
According to some, including Haidut, in his own words described Androstanediol , also known as Hermaphradiol, as the Prime suspect in MPB. I found a study, noting that Finasteride lowers 3a-Diol like 68.9%. The reason for this post is that, common knowledge we know that DHT is responsible for MPB. But according to experiments with DHT, most note that using DHT did not cause increase in hair loss. Haidut stated he not seen any people report of hair loss from DHT or 11 keto DHT. So, could it be possible that Androstanediol be the responsible party. According to this study, Fin decreased 3a Diol G significantly, while reducing hirsutism in women. Also noted in this study was that the lower dose fin is as good as the high dose, and that even though the half life is 8 hours, it build up, so even taken fin every 3 days was just as effective as taking it a full does every day.
"Finasteride treatment was well tolerated by all patients, and no withdrawal was necessary. No variations in menstrual cycle rhythm and body weight were reported. A weak reduction in libido was reported by 5.2% and 10.5% of patients in group 1, whereas by no one patient in group 2 (P<.05 and P<.02 at month 5 and 10, respectively). Mild and transient gastrointestinal discomfort, which disappeared spontaneously, was reported by one patient in group 1. Functional and metabolic parameters did not change significantly throughout the study (data not shown).
Both kinds of treatment induced a significant improvement in the HS (TABLE 1, Table 2) with no between-group difference (df 20; F = 1.27; P = not significant and df 14, F = 1.21, P = not significant, for IH and PCOS patients, respectively). In particular, after 5 months both regimens reduced significantly the HS in patients with IH and PCOS; further improvement was achieved at the end of treatment. In women affected by IH the HS after 10 months of treatment was 48.1% and 52.9% compared with baseline with continuous and intermittent finasteride administration, respectively. In patients with PCOS, the HS at 10 months was 50.5% and 61.4% compared with baseline with continuous and intermittent finasteride administration.
Both therapeutic regimens reduced significantly the serum levels of 3α Diol-G (df 40; F = 1.35; P<.0001 and df 28; F = 167.32; P<.00002 for patients with IH and PCOS, respectively) and DHT (df 40; F = 27206.02; P<.0001 and df 28; F = 1475.27; P<.00001 for patients with IH and PCOS, respectively). However, continuous administration was more effective than intermittent administration in reducing serum levels of 3α Diol-G in patients with IH (df 20; F = 3.46; P=.07) and in women with PCOS (df 14; F = 23.99; P<.002). With regard to the DHT variations, in women with IH, the decrease in serum levels with continuous treatment was significantly greater than that obtained with intermittent administration (df 20; F = 104.41; P<.0001), whereas in women with PCOS, no between-group difference was observed (df 14; F = 0.287; P = not significant). The 3α Diol-G serum levels in women with IH decreased by 68.2% and 64.8% and by 83.4% and 82.4%, at months 5 and 10 in groups 1 and 2, respectively (Table 1Table 1); in patients affected by PCOS the 3α Diol-G decreased by 59.1% and 68.2% and by 69.5% and 77.8%, at months 5 and 10 in groups 1 and 2, respectively (Table 2Table 2). The DHT serum levels in patients with IH decreased by 39.6% and 43.7% and by 40.9% and 45.1% at months 5 and 10 in groups 1 and 2, respectively (Table 1Table 1), whereas in patients with PCOS, the levels decreased by 52.3% and 56.9% and by 48.2% and 53.1% at months 5 and 10 in groups 1 and 2, respectively (Table 2Table 2). Conversely, no significant difference in total T, DHEAS, SHBG, A, and E2 levels was found throughout the study.
The clinical outcome as rated by the patients at the end of treatment was similar into the two groups. In group 1, 84.2% of women rated excellent–good the effect of therapy, 10.5% slight, and 5.2% nill. In group 2, 78.9% of women rated excellent–good the effect of therapy, 21.0%, slight, and no patient considered the effect of therapy ineffective. Furthermore, in both groups no patient complained of worsening hair growth.
The results of this study demonstrate that intermittent low-dose administration of finasteride (2.5 mg every 3 days) is as effective as continuous administration in improving the HS in both patients with IH or PCOS. Interestingly, with both regimens the clinical effects were already evident after 5 months of treatment and further improved after 10 months.
The improvement in HS we observed with both treatments was remarkable; after 10 months of treatment in patients with IH the HS improved by 51.9% and 47.1% with continuous and intermittent finasteride administration, respectively; accordingly in women with PCOS the HS improved by 49.5% and 38.6%, respectively. Although these results may appear overestimated and possibly influenced by the inherent subjectivity of the Ferriman-Gallway scoring system, they are in agreement with many previous studies. Bayram et al. (13x13Bayram, F., Muderris, I.I., Guven, M., and Kelestimur, F. Comparison of high-dose finasteride (5 mg/day) versus low-dose finasteride (2.5 mg/day) in the treatment of hirsutism. Eur J Endocrinol. 2002; 147: 467–471
Crossref | PubMed | Scopus (32) | Google ScholarSee all References13) reported a reduction of 55.7% and 46.1%, respectively, after 12 months of treatment with 2.5 and 5 mg/d of finasteride. Accordingly, Lakryc et al. (11x11Lakryc, E.M., Motta, E.L., Soares, J.M. Jr, Haidar, M.A., de Lima, G.R., and Baracat, E.C. The benefits of finasteride for hirsute women with polycystic ovary syndrome or idiopathic hirsutism. Gynecol Endocrinol. 2003; 17: 57–63
Crossref | PubMed | Google ScholarSee all References11) found a reduction in HS by 47.7% after 6 months of treatment with 5 mg of finasteride. Faloia et al. (16x16Faloia, E., Filipponi, S., Mancini, V., Di Marco, S., and Mantero, F. Effect of finasteride in idiopathic hirsutism. J Endocrinol Invest. 1998; 21: 694–698
PubMed | Google ScholarSee all References16) also reported a 32.4% reduction in HS after 6 months of treatment with 5 mg of finasteride.
The pharmacokinetic profile of low-dose intermittent finasteride could explain its effectiveness. Finasteride has a high affinity for the 5α-R type 2. The maximum effect on plasma DHT is achieved at a single daily dose from 0.5–5 mg; noteworthy, administration of more than 5 mg was not more effective in reducing DHT plasma levels. The half-life of finasteride has been reported to range from 4.7–7.1 hours; slow accumulation occurs with multiple doses, therefore a single dose suppresses serum DHT levels for up to 4 days, much longer than one would expect on the basis of the half-life of the drug (17x17Steiner, J.F. Clinical pharmacokinetics and pharmacodynamics of finasteride. Clin Pharmacokinet. 1996; 30: 16–27
Crossref | PubMed | Scopus (87) | Google ScholarSee all References, 18x18Gormley GJ, Stoner E, Rittmaster RS, Gregg H, Thompson DL, Lasseter KC, et al. Effects of finasteride (MK-906), a 5 α-reductase inhibitor, on circulating androgens in male volunteers. J Clin Endocrinol Metab 1990;70(4):1136–41.
Google ScholarSee all References). Moreover, after oral intake finasteride is extensively metabolized through oxidative pathways, and both ω-hydroxyfinasteride and the monocarboxy metabolite show bioactivity in vitro (17x17Steiner, J.F. Clinical pharmacokinetics and pharmacodynamics of finasteride. Clin Pharmacokinet. 1996; 30: 16–27
Crossref | PubMed | Scopus (87) | Google ScholarSee all References17). High receptor affinity, slow accumulation, and bioactivity of metabolites may explain the effectiveness of the regimen investigated.
In the present study, after 5 months of treatment we found a significant decrease in DHT and 3α Diol-G levels but no variations in T, DHEAS, SHBG, A, and E2 levels. However, continuous administration had a significantly greater reduction in DHT levels in women with IH and in 3α Diol-G in women with PCOS. This result could be explained by the different amount of drug administered in the two groups.
Although by using 5α-R inhibitors one could expect a concomitant increase in T serum levels, the absence of variation in serum T levels we found is in agreement with other studies that reported significant reduction in DHT but not in T levels (11x11Lakryc, E.M., Motta, E.L., Soares, J.M. Jr, Haidar, M.A., de Lima, G.R., and Baracat, E.C. The benefits of finasteride for hirsute women with polycystic ovary syndrome or idiopathic hirsutism. Gynecol Endocrinol. 2003; 17: 57–63
Crossref | PubMed | Google ScholarSee all References11). Dihydrotestosterone is a marker of 5α-R activity and therefore, serum levels are directly influenced by finasteride-induced enzyme inhibition. Serum levels of T, on the contrary, are regulated by several mechanisms influencing the production, metabolism, and distribution in the fatty tissue and conversion to E2, all contributing in stabilizing serum T levels. The low dosage of drug used and the multiple factors at play in the regulation of serum T levels may explain the reduction in DHT levels without a concomitant increase in T serum levels.
The unchanged serum T levels throughout the study and the very low dosage of drug with intermittent administration may explain the significantly lower incidence of side effects in group 2 patients compared with those in group 1. Finally, finasteride is an expensive drug and the intermittent regimen allows the cost of treatment to be reduced by two-thirds.
In conclusion, this study demonstrates for the first time that a low-dose (2.5 mg) administration of finasteride, given every 3 days, is as effective as conventional continuous administration in reducing the HS in patients affected by PCOS or IH. Moreover, the intermittent low-dose regimen has the advantage to be safer and less expensive compared with conventional continuous administration."
"Finasteride treatment was well tolerated by all patients, and no withdrawal was necessary. No variations in menstrual cycle rhythm and body weight were reported. A weak reduction in libido was reported by 5.2% and 10.5% of patients in group 1, whereas by no one patient in group 2 (P<.05 and P<.02 at month 5 and 10, respectively). Mild and transient gastrointestinal discomfort, which disappeared spontaneously, was reported by one patient in group 1. Functional and metabolic parameters did not change significantly throughout the study (data not shown).
Both kinds of treatment induced a significant improvement in the HS (TABLE 1, Table 2) with no between-group difference (df 20; F = 1.27; P = not significant and df 14, F = 1.21, P = not significant, for IH and PCOS patients, respectively). In particular, after 5 months both regimens reduced significantly the HS in patients with IH and PCOS; further improvement was achieved at the end of treatment. In women affected by IH the HS after 10 months of treatment was 48.1% and 52.9% compared with baseline with continuous and intermittent finasteride administration, respectively. In patients with PCOS, the HS at 10 months was 50.5% and 61.4% compared with baseline with continuous and intermittent finasteride administration.
Both therapeutic regimens reduced significantly the serum levels of 3α Diol-G (df 40; F = 1.35; P<.0001 and df 28; F = 167.32; P<.00002 for patients with IH and PCOS, respectively) and DHT (df 40; F = 27206.02; P<.0001 and df 28; F = 1475.27; P<.00001 for patients with IH and PCOS, respectively). However, continuous administration was more effective than intermittent administration in reducing serum levels of 3α Diol-G in patients with IH (df 20; F = 3.46; P=.07) and in women with PCOS (df 14; F = 23.99; P<.002). With regard to the DHT variations, in women with IH, the decrease in serum levels with continuous treatment was significantly greater than that obtained with intermittent administration (df 20; F = 104.41; P<.0001), whereas in women with PCOS, no between-group difference was observed (df 14; F = 0.287; P = not significant). The 3α Diol-G serum levels in women with IH decreased by 68.2% and 64.8% and by 83.4% and 82.4%, at months 5 and 10 in groups 1 and 2, respectively (Table 1Table 1); in patients affected by PCOS the 3α Diol-G decreased by 59.1% and 68.2% and by 69.5% and 77.8%, at months 5 and 10 in groups 1 and 2, respectively (Table 2Table 2). The DHT serum levels in patients with IH decreased by 39.6% and 43.7% and by 40.9% and 45.1% at months 5 and 10 in groups 1 and 2, respectively (Table 1Table 1), whereas in patients with PCOS, the levels decreased by 52.3% and 56.9% and by 48.2% and 53.1% at months 5 and 10 in groups 1 and 2, respectively (Table 2Table 2). Conversely, no significant difference in total T, DHEAS, SHBG, A, and E2 levels was found throughout the study.
The clinical outcome as rated by the patients at the end of treatment was similar into the two groups. In group 1, 84.2% of women rated excellent–good the effect of therapy, 10.5% slight, and 5.2% nill. In group 2, 78.9% of women rated excellent–good the effect of therapy, 21.0%, slight, and no patient considered the effect of therapy ineffective. Furthermore, in both groups no patient complained of worsening hair growth.
The results of this study demonstrate that intermittent low-dose administration of finasteride (2.5 mg every 3 days) is as effective as continuous administration in improving the HS in both patients with IH or PCOS. Interestingly, with both regimens the clinical effects were already evident after 5 months of treatment and further improved after 10 months.
The improvement in HS we observed with both treatments was remarkable; after 10 months of treatment in patients with IH the HS improved by 51.9% and 47.1% with continuous and intermittent finasteride administration, respectively; accordingly in women with PCOS the HS improved by 49.5% and 38.6%, respectively. Although these results may appear overestimated and possibly influenced by the inherent subjectivity of the Ferriman-Gallway scoring system, they are in agreement with many previous studies. Bayram et al. (13x13Bayram, F., Muderris, I.I., Guven, M., and Kelestimur, F. Comparison of high-dose finasteride (5 mg/day) versus low-dose finasteride (2.5 mg/day) in the treatment of hirsutism. Eur J Endocrinol. 2002; 147: 467–471
Crossref | PubMed | Scopus (32) | Google ScholarSee all References13) reported a reduction of 55.7% and 46.1%, respectively, after 12 months of treatment with 2.5 and 5 mg/d of finasteride. Accordingly, Lakryc et al. (11x11Lakryc, E.M., Motta, E.L., Soares, J.M. Jr, Haidar, M.A., de Lima, G.R., and Baracat, E.C. The benefits of finasteride for hirsute women with polycystic ovary syndrome or idiopathic hirsutism. Gynecol Endocrinol. 2003; 17: 57–63
Crossref | PubMed | Google ScholarSee all References11) found a reduction in HS by 47.7% after 6 months of treatment with 5 mg of finasteride. Faloia et al. (16x16Faloia, E., Filipponi, S., Mancini, V., Di Marco, S., and Mantero, F. Effect of finasteride in idiopathic hirsutism. J Endocrinol Invest. 1998; 21: 694–698
PubMed | Google ScholarSee all References16) also reported a 32.4% reduction in HS after 6 months of treatment with 5 mg of finasteride.
The pharmacokinetic profile of low-dose intermittent finasteride could explain its effectiveness. Finasteride has a high affinity for the 5α-R type 2. The maximum effect on plasma DHT is achieved at a single daily dose from 0.5–5 mg; noteworthy, administration of more than 5 mg was not more effective in reducing DHT plasma levels. The half-life of finasteride has been reported to range from 4.7–7.1 hours; slow accumulation occurs with multiple doses, therefore a single dose suppresses serum DHT levels for up to 4 days, much longer than one would expect on the basis of the half-life of the drug (17x17Steiner, J.F. Clinical pharmacokinetics and pharmacodynamics of finasteride. Clin Pharmacokinet. 1996; 30: 16–27
Crossref | PubMed | Scopus (87) | Google ScholarSee all References, 18x18Gormley GJ, Stoner E, Rittmaster RS, Gregg H, Thompson DL, Lasseter KC, et al. Effects of finasteride (MK-906), a 5 α-reductase inhibitor, on circulating androgens in male volunteers. J Clin Endocrinol Metab 1990;70(4):1136–41.
Google ScholarSee all References). Moreover, after oral intake finasteride is extensively metabolized through oxidative pathways, and both ω-hydroxyfinasteride and the monocarboxy metabolite show bioactivity in vitro (17x17Steiner, J.F. Clinical pharmacokinetics and pharmacodynamics of finasteride. Clin Pharmacokinet. 1996; 30: 16–27
Crossref | PubMed | Scopus (87) | Google ScholarSee all References17). High receptor affinity, slow accumulation, and bioactivity of metabolites may explain the effectiveness of the regimen investigated.
In the present study, after 5 months of treatment we found a significant decrease in DHT and 3α Diol-G levels but no variations in T, DHEAS, SHBG, A, and E2 levels. However, continuous administration had a significantly greater reduction in DHT levels in women with IH and in 3α Diol-G in women with PCOS. This result could be explained by the different amount of drug administered in the two groups.
Although by using 5α-R inhibitors one could expect a concomitant increase in T serum levels, the absence of variation in serum T levels we found is in agreement with other studies that reported significant reduction in DHT but not in T levels (11x11Lakryc, E.M., Motta, E.L., Soares, J.M. Jr, Haidar, M.A., de Lima, G.R., and Baracat, E.C. The benefits of finasteride for hirsute women with polycystic ovary syndrome or idiopathic hirsutism. Gynecol Endocrinol. 2003; 17: 57–63
Crossref | PubMed | Google ScholarSee all References11). Dihydrotestosterone is a marker of 5α-R activity and therefore, serum levels are directly influenced by finasteride-induced enzyme inhibition. Serum levels of T, on the contrary, are regulated by several mechanisms influencing the production, metabolism, and distribution in the fatty tissue and conversion to E2, all contributing in stabilizing serum T levels. The low dosage of drug used and the multiple factors at play in the regulation of serum T levels may explain the reduction in DHT levels without a concomitant increase in T serum levels.
The unchanged serum T levels throughout the study and the very low dosage of drug with intermittent administration may explain the significantly lower incidence of side effects in group 2 patients compared with those in group 1. Finally, finasteride is an expensive drug and the intermittent regimen allows the cost of treatment to be reduced by two-thirds.
In conclusion, this study demonstrates for the first time that a low-dose (2.5 mg) administration of finasteride, given every 3 days, is as effective as conventional continuous administration in reducing the HS in patients affected by PCOS or IH. Moreover, the intermittent low-dose regimen has the advantage to be safer and less expensive compared with conventional continuous administration."